|
COPD & Asthma Newsletter Series
A complete list of the Peer-Reviewed e-Newsletter Series sponsored by AstraZeneca LP.
|
CLICK HERE to update your email preferences so you don't miss any of our peer-reviewed COPD and Asthma articles!
Patients with chronic obstructive pulmonary disease (COPD) and asthma often present to health care providers in the primary care setting, including nurse practitioners (NPs) and physician assistants (PAs). A vast array of information on the diagnosis and management of patients with asthma and COPD is available to practicing clinicians; thus, educational materials that contextualize learnings for the practice-focused NP or PA are useful.
Each issue in the Focus on Asthma and COPD e-newsletter series (one series for NPs and one for PAs) reviews a current topic in the management of these respiratory diseases. Case studies illustrate common issues related to diagnosis and treatment of asthma and COPD, while key points emphasize educational imperatives. Practice tools and links to additional information also are featured.
E-newsletter Series for NPs:
Authors:
Rosemary Young, APRN
Kevin Murphy, MD
Jennifer Banfield, APRN, FNP
Peer-Reviewed e-Newsletter, Issue 1 :
Review of the 2009 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for the Pharmacological Management of Chronic Obstructive Pulmonary Disease
Original Publish Date = 6/29/2010
Peer-Reviewed e-Newsletter, Issue 2 :
Reversibility of Airflow Obstruction in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Original Publish Date = 2/11/2011
Peer-Reviewed e-Newsletter, Issue 3 :
Devices for Aerosol Delivery in the Treatment of Adults With Asthma and Chronic Obstructive Pulmonary Disease (COPD) in the United States
Original Publish Date = 7/22/2011
Peer-Reviewed e-Newsletter, Issue 4 :
Gastroesophageal Reflux Disease in Older Children and Adults With Asthma
Original Publish Date = 12/29/2011
E-newsletter Series for PAs:
Author:
Gabriel Ortiz, MPAS, PA-C, DFAAPA
Peer-Reviewed e-Newsletter, Issue 1 :
Summary Information for Inhaled Corticosteroid and Long-Acting β 2-Adrenergic Agonist Combination Product Use in Patients in the United States Who Have Asthma or Chronic Obstructive Pulmonary Disease
Original Publish Date = 8/26/2010
Peer-Reviewed e-Newsletter, Issue 2 :
Applying the 2009 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines for the Pharmacological Management of Chronic Obstructive Pulmonary Disease in Clinical Practice Original Publish Date = 12/9/2010
Peer-Reviewed e-Newsletter, Issue 3 :
The Importance of Accurate Obstructive Respiratory Disease Diagnoses: A Comparison of Asthma and Chronic Obstructive Pulmonary Disease Original
Original Publish Date = 5/15/2011
Peer-Reviewed e-Newsletter, Issue 4 :
Tools for Diagnosis and Assessment of Asthma and Chronic Obstructive Pulmonary Disease in Clinical Practice
Original Publish Date = 10/31/2011
Recent Respiratory News
- Recent Publications of Interest
Findings from a recent randomized, parallel-group, placebo-controlled study of COPD patients (N=1142) showed addition of azithromycin 250 mg daily to usual care for 1 year resulted in a significantly reduced frequency of exacerbations compared with placebo plus usual care (1.48 versus 1.83 per patient-year, respectively). However, azithromycin treatment was associated with an increased incidence of hearing decrements compared with placebo. The abstract of the study is available at: http://www.ncbi.nlm.nih.gov/pubmed/21864166
Findings from a 1-year, randomized, placebo-controlled study of 278 preschool children with recurrent wheezing and high asthma risk showed that intermittent nebulized corticosteroid treatment was as effective as daily nebulized corticosteroid therapy for controlling exacerbation frequency. Patients received one of two treatments: 1) intermittent high-dose budesonide inhalation suspension (1 mg twice daily) for 7 days, initiated at the first sign of respiratory tract illness, 2) daily low-dose regimen (0.5 mg nightly). The intermittent regimen reduced the cumulative inhaled corticosteroid dose threefold versus the daily regimen. The abstract of the article is available at: http://www.ncbi.nlm.nih.gov/pubmed/22111718
Indacaterol (Arcapta Neohaler), a long-acting β2-adrenergic agonist, was approved by the US FDA for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in people with COPD including chronic bronchitis and/or emphysema at a dose of 75 µg. Press announcement available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm261649.htm
- Latest COPD, Asthma, and Allergy Guidelines Updates
Joint guidelines developed by the American College of Physicians (ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), and European Respiratory Society (ERS) were recently published in August 2011 and represent an update of the 2007 ACP clinical practice guideline on diagnosis and management of COPD. Seven important recommendations were made relating to:
- Spirometry as a diagnostic tool
- COPD management strategies with regard to inhaled therapies
(4 recommendations)
- Pulmonary rehabilitation
- Continuous oxygen therapy
More information is available at: http://www.thoracic.org/statements/resources/respiratory-disease-adults/copd-guideline-acp-ats-ers-accp%20-abstract.pdf
In September 2011, new clinical guidelines from the American Thoracic Society (ATS) were published on the use and interpretation of fractional exhaled nitric oxide (FENO). In the past, interpretation of FENO values in the clinical setting was not standardized; the new ATS guidelines specify cut points for FENO levels that indicate the likelihood that patients will respond to inhaled corticosteroid (ICS) therapy or an increase in the ICS dose. They also recommend use of FENO testing to support a diagnosis of asthma and for monitoring compliance with ICS therapy. These guidelines are published in the American Journal of Respiratory and Critical Care Medicine (2011;184:602-615): http://ajrccm.atsjournals.org/cgi/reprint/184/5/602. Accessed December 13, 2011.
The full report of the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) international guidelines will be available on their website in late December 2011 at: http://www.goldcopd.org/guidelines-resources.html. A summary of the 2011 updated report is available at: http://www.goldcopd.org/uploads/users/files/GOLD2011_Summary.pdf.
The full report of the 2010 GOLD guidelines is available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html and the pocket guide is available at: http://www.goldcopd.org/uploads/users/files/GOLD_Pocket_2010Mar31.pdf
The National Asthma Education and Prevention Program (NAEPP) and the NHLBI of the NIH publish US guidelines for the diagnosis and management of asthma, which were last updated in 2007. More information is available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
Guidelines for the diagnosis and management of food allergy in the United States were published by the National Institute of Allergy and Infectious Diseases (NIAID) in December 2010. More information is available at: http://www.niaid.nih.gov/topics/foodallergy/clinical/pages/default.aspx
CLICK HERE if you have suggestions for future topics.
|
|
|
|
|
|
|